ArticlePharmacoepidemiology and drug safety2026
Impact of COVID-19 Restrictions on Estimating Causal Effects: Fluoroquinolones and Tendon Rupture.
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe COVID-19 pandemic disrupted healthcare services, potentially affecting causal effect estimation using real-world data. As a case study, we replicated a cohort study using Clinical Practice Research Datalink Aurum to evaluate whether pandemic-related disruptions influenced the measured association between fluoroquinolone use and tendon rupture.
methodsWe included adults initiating fluoroquinolones/cephalosporins during 1 January 2006-31 March 2023. Four analyses compared treatment effect estimates using different periods for exposure and outcome ascertainment: pre-pandemic only, pre-pandemic exposure with follow-up extending through the pandemic, all available data and post-pandemic only. We estimated hazard ratios (HRs) for tendon rupture using Cox regression.
resultsAmong 891 968 fluoroquinolone users and 895 229 cephalosporin users, fluoroquinolone users had more comorbidities than cephalosporin users in the pre-pandemic period but fewer in the post-pandemic period. Pre-pandemic analysis showed an increased risk of tendon rupture associated with fluoroquinolones (Propensity score weighted [PSW]-HR: 1.94; 95% CI: 1.46-2.59), consistent with previous evidence. Estimates using all available data were similar for the overall study period (PSW-HR: 1.91; 95% CI: 1.46-2.51) and the pre-pandemic period (PSW-HR: 1.96; 95% CI: 1.47-2.61) but were less precise during/post-pandemic period (PSW-HR: 1.57; 95% CI: 0.72-3.41) with no evidence of a period-treatment interaction (PSW-HR: 0.80; 95% CI: 0.35-1.84). Post-pandemic analysis showed very few events among cephalosporin users but not fluoroquinolone users with a larger but imprecise estimate (PSW-HR: 3.32; 95% CI: 0.62-17.72).
conclusionIn this case study, there was no clear evidence that pandemic-related healthcare disruptions materially altered causal estimates, albeit with limited power to detect differences between before and during/post-pandemic effects. Studies using real-world data across the pandemic should routinely examine temporal changes in baseline characteristics and outcome incidence.
Indexed as
Identifiers
42880886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.